JUN 18, 2020 8:29 AM PDT

FDA Cancels Emergency Approval for Hydroxychloroquine

WRITTEN BY: Annie Lennon

The US Food and Drug Administration (FDA) has decided to cancel emergency use authorization for Hydroxychloroquine and Chloroquine. The news follows results from a new study showing that Hydroxychloroquine is ineffective in preventing infections by COVID-19.

The FDA initially gave the drugs emergency use authorization in March after preliminary studies demonstrated their potential to treat COVID-19. Prescriptions for the drugs skyrocketed by almost 2000% after President Donald Trump announced them to be possible treatments for the coronavirus in March. 

The FDA's recent decision to cancel the drugs' emergency approval comes after the results of the first randomized, placebo-controlled trial studying Hydroxychloroquine. Examining its effects in 821 people across the US and Canada after exposure to the virus, the study found that the drug worked no better than a placebo in preventing COVID-19 infections. 

Due to these findings, and results of some other studies, the FDA said in a notice that the Hydrocholoquine and Chloroquine are 'unlikely to be effective' against the coronavirus. 

"Additionally, in light of ongoing serious cardiac adverse events and other serious side effects, the known and potential benefits of CQ and HCQ no longer outweigh the known and potential risks for the authorized use," the FDA continued in their statement

Due to the most recent study, the World Health Organization has also decided to drop Hydrochloroquine from its global study of potential treatments for COVID-19.

Aside from treating malaria, Hyrdrochloroquine is also used to treat rheumatoid arthritis and lupus. Although some studies are still underway on its ability to treat COVID-19, research until now has created a growing consensus that it is ineffective. 

Currently, the FDA has not approved any drugs to treat the coronavirus. The agency did, however, give Remdesivir emergency use authorization on May 1st, 2020. This came after promising results from clinical trials showing it capable of reducing recovery times from 15 to 11 days. 

 

Sources: CNBCFDAThe New England Journal of Medicine 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 14, 2020
Cell & Molecular Biology
A Fungal Compound That Triggers Self-Destruction in Cancer Cells
JUN 14, 2020
A Fungal Compound That Triggers Self-Destruction in Cancer Cells
To describe it in a very basic way, cancer is uncontrolled cell growth. A number of processes regulate various aspects o ...
JUN 12, 2020
Technology
How A Computer Sea Slug Can Get Addicted To A Drug
JUN 12, 2020
How A Computer Sea Slug Can Get Addicted To A Drug
Sea slugs have long been used to study brain models especially in research concerned with memory and learning. Now, rese ...
JUN 26, 2020
Cancer
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
JUN 26, 2020
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immatu ...
JUN 19, 2020
Drug Discovery & Development
First Treatment To Prevent Anaphylaxis
JUN 19, 2020
First Treatment To Prevent Anaphylaxis
People living with food or drug allergies are always faced with potential life-threatening anaphylactic shock. Currently ...
JUL 08, 2020
Drug Discovery & Development
Common Blood Pressure Drugs May Prevent Colon Cancer
JUL 08, 2020
Common Blood Pressure Drugs May Prevent Colon Cancer
Colon cancer is the third most common cancer and the second leading cause of death by cancer around the world. Now, rese ...
AUG 10, 2020
Cardiology
Can Statins be Used to Treat Strokes?
AUG 10, 2020
Can Statins be Used to Treat Strokes?
When a blood clot forms in an artery that supplies the brain with oxygen, obstructing it, a stroke can occur. Strokes ca ...
Loading Comments...